Comparing two heart stents in people treated for narrowed coronary arteries
Tests a new biodegradable-polymer stent against standard stents in adults with narrowed heart arteries.
Plain-language title generated from the registry record
Registry title: Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated With Percutaneous Coronary Intervention
Key facts
- Where
- Aalborg, Aarhus, and Odense, DenmarkSee the 3 sites
Where in Denmark
- Aalborg University HospitalAalborg, DenmarkTaking people
- Aarhus University HospitalAarhus, DenmarkTaking people
- Odense University HospitalOdense, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Odense University Hospital
- Trial code
- NCT06692140
- Record updated
- 22 October 2026
- Original description
The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary interventionRead full original descriptionShow less
Randomized Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated With Percutaneous Coronary Intervention in an All Comer Population (The SORT OUT XII Trial)
The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary intervention
Inclusion: All patients aged ≥18 years who are eligible for treatment with one or several drug-eluting coronary stents.
Exclusion: Allergic to study related treatment; Age < 18 years; Not able to consent to study participating (eg. intubated patients); Unstable circuit or in cardiogenic shock and therefore not able to understand the information and purpose of the study; Do not speak Danish; Already included in the SORT OUT XII study; Life expectancy <1 year.